GC Cell Corp
144510
Company Profile
Business description
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.
Contact
30 beongil to giheung-gu
Gyeonggi
107 Lee Hyun
Yongin16 924
KORT: +82 312609600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
797
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,225.73 | 19.66 | 0.24% |
| DAX 40 | 24,264.29 | 5.49 | 0.02% |
| Dow JONES (US) | 46,830.55 | 123.97 | 0.27% |
| FTSE 100 | 9,407.22 | 3.65 | 0.04% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,939.73 | 50.81 | -0.22% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,732.13 | 3.00 | -0.04% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |